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Abstract
Rhabdomyosarcoma (RMS) is a mesenchymal tumor of soft tissue in children that originates from a myogenic
differentiation defect. Expression of SNAIL transcription factor is elevated in the alveolar subtype of RMS (ARMS),
characterized by a low myogenic differentiation status and high aggressiveness. In RMS patients SNAIL level increases
with higher stage. Moreover, SNAIL level negatively correlates with MYF5 expression. The differentiation of human
ARMS cells diminishes SNAIL level. SNAIL silencing in ARMS cells inhibits proliferation and induces differentiation
in vitro, and thereby completely abolishes the growth of human ARMS xenotransplants in vivo. SNAIL silencing induces
myogenic differentiation by upregulation of myogenic factors and muscle-specific microRNAs, such as miR-206. SNAIL
binds to the MYF5 promoter suppressing its expression. SNAIL displaces MYOD from E-box sequences (CANNTG) that
are associated with genes expressed during differentiation and G/C rich in their central dinucleotides. SNAIL silencing
allows the re-expression of MYF5 and canonical MYOD binding, promoting ARMS cell myogenic differentiation. In
differentiating ARMS cells SNAIL forms repressive complex with histone deacetylates 1 and 2 (HDAC1/2) and regulates
their expression. Accordingly, in human myoblasts SNAIL silencing induces differentiation by upregulation of
myogenic factors. Our data clearly point to SNAIL as a key regulator of myogenic differentiation and a new promising
target for future ARMS therapies.
Introduction
Rhabdomyosarcoma (RMS) is the most frequently
occurring soft tissue sarcoma among children and ado-
lescents, however, rare instances of the disease have been
noted in adults. Based on histological analysis of the
tumor, two major RMS subtypes may be distinguished:
embryonal (ERMS) and alveolar (ARMS). ERMS is usually
associated with better survival and typically occurs in the
head and neck and urogenital tract. ARMS occurs in the
extremities and trunk and generally has a significantly
worse prognosis1–3. High aggressiveness of ARMS sub-
type is associated with presence of PAX3-FOXO1 or
PAX7-FOXO1 fusion genes and increased levels of MET
receptor, a member of tyrosine kinase receptors family
(RTK), which is associated with metastatic potential of
RMS cells2,4. RMS development is likely connected to a
differentiation defect of stem cells or early progenitors,
such as mesenchymal stem cells or satellite cells/
myoblasts3,5,6.
Myogenic differentiation is regulated by different early
and late myogenic factors. These basic helix-loop-helix
(bHLH) transcription activators contain a conserved DNA
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binding domain, that recognizes the enhancer box (E-box)
motif[7]. Myogenic factor 5 (MYF5) and myogenic dif-
ferentiation 1 (MYOD/MYOD1) are responsible for the
early stages of differentiation, whereas myogenin (MYOG)
and myogenic factor 6 (MRF4) are responsible for term-
inal differentiation7. Those myogenic factors regulate
genes and muscle-specific microRNAs. An interesting
example is miR-206, which is induced by MYOD to
enhance differentiation and facilitate cell cycle exit8.
Aberrations within the regulatory myogenic pathway
described above may be one of the crucial causes of the
rhabdomyosarcoma development3,4.
In our previous work, we observed that aggressive
ARMS tumors display higher expression of the SNAIL
gene and that SNAIL expression positively correlates with
PAX3/7-FOXO19. SNAIL (snail family zinc finger 1;
SNAI1) is a member of the group of zinc finger tran-
scription factors. The SNAIL family consists of 3 mem-
bers: SNAIL (SNAI1), SLUG (SNAI2) and SMUG
(SNAI3). SNAIL plays an eminent role in the epithelial to
mesenchymal transition (EMT), the main mechanism
responsible for both embryogenesis and the invasiveness
and metastasis of neoplasms10–12. By binding to target
E-box sequences (CANNTG), SNAIL acts as a transcrip-
tional repressor, but it may also work as a gene activator13.
SNAIL, causes epigenetic changes in chromatin structure,
mainly by recruiting histone deacetylases (HDACs)14.
The role of SNAIL in non-epithelial tumors is poorly
understood. Recent data have provided evidence that
SNAIL plays an important role in cells of mesenchymal
origin. Murine fibroblasts expressing SNAIL in epithelial
tumor microenvironment support metastasis, given their
mechanical properties15. Moreover, when SNAIL
expression is reactivated in mesenchymal cells, they may
become invasive, whereas SNAIL-deficient fibroblasts do
not display invasive capabilities16. Activated mesenchymal
cells display SNAIL expression, and SNAIL seems to play
an important role in the communication between the
stroma and the tumor and it can facilitate the conversion
of cancer cells to stromal cells17. In sarcomas and fibro-
sarcomas, SNAIL levels are elevated17. However, the
precise mechanism of its action remains unknown.
The mechanistic role of SNAIL in the biology of ARMS
has not been investigated, although, the important role of
SNAIL in murine myogenesis has been described pre-
viously18. SNAIL zinc-finger binding domains recognize
the same E-box sequence as bHLH myogenic transcrip-
tion factors. The repressive complex of SNAIL with
HDACs binds and excludes MYOD from G/C-rich E-box
motifs in murine satellite cells, thereby inhibiting myo-
genic differentiation. In RMS SNAIL expression is higher
in ARMS tumor9 that is associated with worse prognosis
and SNAIL is a mediator of NOTCH pathway in ERMS
subtype19.
Here, we demonstrate for the first time that SNAIL
blocks human ARMS differentiation and promotes tumor
development. Importantly, our study describes the mole-
cular mechanism of SNAIL, which deregulates growth
and myogenic differentiation of ARMS cells through
interference with the early myogenic transcription factors,
MYF5 and MYOD.
Results
SNAIL expression is associated with RMS myogenic
differentiation
Because RMS can originate from the impaired differ-
entiation of myogenic progenitors, we analyzed the
expression of myogenic regulatory factors and SNAIL in
patient samples obtained from two major RMS subtypes,
ERMS and ARMS. Bioinformatical analysis of microarray
data deposited in GEO database (ref. 20) was performed
according to literature21 and revealed that in 158 RMS
patients samples SNAIL level negatively correlated with
MYF5 level (Fig. 1a) and positively correlated with MYOD
(Fig. 1b). In a group of 158 samples SNAIL level turned
out to be significantly increased in RMS samples from
patients displaying the stages of the disease 2, 3, and 4
compared to stage 1, what suggested an important role of
SNAIL in RMS progression (Fig. 1c). Moreover, SNAIL
level was elevated in ARMS compared to ERMS (Fig. 1d),
what is in accordance with the staging results, because
ARMS is not included in stage 1 due to more unfavorable
histology. Those data indicated that SNAIL may play an
important role in the development of less differentiated
ARMS tumors that are associated with worse prognosis.
SNAIL levels were also significantly increased in RH41
and RH30 ARMS cell lines compared with RD and RH18
ERMS cell lines, and the levels were comparable with the
SNAIL level in human myoblasts at early passages,
whereas differentiated myotubes displayed the diminished
SNAIL levels that were comparable with ERMS cells
(Fig. 1e). Forced myogenic differentiation of RH30 ARMS
cells for 7 days significantly diminished SNAIL expression
at the mRNA and protein levels (Fig. 1f). These results
suggested the direct association of SNAIL expression with
myogenic differentiation.
SNAIL silencing changes the ARMS phenotype and
completely inhibits tumor growth in mice
Since ARMS tumors and cell lines display increased
SNAIL levels, we silenced SNAIL with siRNA in RH41
and RH30 ARMS cells and treated the cells with differ-
entiating medium for the next 2 days. Transient SNAIL
silencing diminished the cell proliferation and induced the
acquisition of a more elongated (spindle-shaped) pheno-
type (Fig. 2a). Moreover, two different siRNA sequences
against SNAIL resulted in acquisition of the elongated
phenotype (spindle shape) in RH30 and RH41 cells
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Fig. 1 SNAIL expression is associated with RMS subtype and myogenic differentiation. a Expression of early and late myogenic factors in 158
RMS samples was estimated previously by microarray and deposited in GEO database with accession number: GSE92689 (ref. 20). SNAIL level negatively
correlates with MYF5 level in RMS (Pearson correlation). b SNAIL level positively correlates with MYOD level in RMS (Pearson correlation). R—Pearson
correlation coefficient; p—significance value (c) Increased SNAIL levels in RMS stage 2,3 and 4 compared to 1 were demonstrated in a group of 158
RMS samples (microarray data, GEO database GSE92689). The data are presented as Whisker plots min to max. d Increased SNAIL level in ARMS
compared to ERMS was demonstrated in a group of 158 RMS samples (microarray data, GEO database GSE92689). The data are presented as Whisker
plots min to max. e SNAIL expression was quantified by qPCR using the ΔCt quantification method and GAPDH as a housekeeping gene control in
ARMS and ERMS cell lines and human primary myoblasts. The SNAIL level is increased in RH30 and RH41 ARMS cell lines compared to RD and RH18
ERMS cell lines, and the level is comparable with the SNAIL level in myoblasts at the early passage (undiff.), whereas in the differentiated myotubes
(diff.) SNAIL level is more comparable with ERMS; n= 3. f Differentiation of RH30 cells by culture in medium supplemented with 2% HS for 7 days
downregulates SNAIL expression at the mRNA level (qPCR) and protein level (Western blotting); n= 4. The data represent the mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.001
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(Supplementary Figure 1). Next, we stably silenced SNAIL
by transduction of RH30 cells with mixture of three
shRNA vectors (shSNAIL cells). Control cells were
modified with scrambled shRNA (shCTRL). In the stable
cell line SNAIL mRNA and protein downregulation was
verified (Fig. 2b). Stable SNAIL silencing and cell culture
in differentiating medium for 6 days resulted in mor-
phological changes and the acquisition of a strongly
elongated and polarized phenotype, resembling myotubes
(Fig. 2c). The differentiation of RH30 shSNAIL cells for
7 days diminished proliferation and resulted in growth
arrest at the G0/G1 phase and the diminished percentage
of cells in S phase (Fig. 2d).
To investigate the effect of SNAIL silencing in vivo, we
subcutaneously implanted RH30 cells into immunodefi-
cient NOD-SCID mice, and we evaluated tumor growth
for 21 days. SNAIL silencing completely abolished the
development of any tumors, whereas wild type (WT) and
control (shCTRL) tumors grew in mice, reaching up to
600mm3 in size and 1 to 1.5 g in weight (Fig. 3a). Those
results indicated for the first time that SNAIL is a crucial
factor that regulates RMS growth.
To confirm that the observed effects are SNAIL
dependent, we transduced RH30 shSNAIL cells with
lentiviral vectors encoding GFP-P2A-SNAIL, resulting in
the partial restoration of SNAIL protein expression and
incomplete reversal of the phenotype (Fig. 3b). Subse-
quently, we implanted these cells into mice. Tumor
development was noted within 28 days after implantation.
However, these tumors were significantly smaller than the
control tumors probably because the SNAIL level was not
totally restored in these cells (Fig. 3c). Both tumor types
displayed similar morphology (Fig. 3d), suggesting that
only cells with a restored SNAIL level could form tumors
in mice. To model clinical effect of SNAL silencing, we
performed three injections of 3 μg/kg siRNA against
SNAIL into growing RH30 tumors. The antitumor effect
of SNAIL siRNA treatment tended to be visible at the end
of therapy (Fig. 3e). Interestingly, the therapy resulted in
appearance of differentiated morphology of tumors trea-
ted with SNAIL siRNA (Fig. 3f) and those regions dis-
played diminished SNAIL expression (Fig. 3g).
SNAIL silencing in ARMS directly upregulates MYF5 and
excludes MYOD from its DNA binding sites
Since expression of SNAIL negatively correlated with
expression of myogenic factors, we hypothesized that
complete inhibition of tumor growth in vivo may be a
result of the myogenic differentiation of the cells. To
evaluate this hypothesis, we investigated the effect of
SNAIL on different early and late myogenic factors.
SNAIL did not exert the significant effect on MYOD
expression (Fig. 4a). Interestingly, the nuclei of
RH30 shSNAIL cells displayed strong MYF5 expression,
whereas control cells did not express MYF5 what was
confirmed by Western blot analysis (Fig. 4b). Similarly,
MYF5 mRNA was not expressed in RH30 cells, but
SNAIL silencing strongly induced its expression in both
undifferentiated and differentiated cells (Fig. 4c).
Accordingly, we stably silenced SNAIL level in RH41 cells
by transduction of RH41 cells with shRNA vectors
(shSNAIL cells) and protein downregulation was verified
(Supplementary Figure 2a). In those cells MYF5 expres-
sion was also induced (Fig. 4d). Moreover, temporal
silencing of SNAIL expression for three days was suffi-
cient for the induction of MYF5 expression in different
ARMS cell lines: RH30 and RH41 (Fig. 4e). Interestingly,
transfection of RH30 cells with the miR-30a precursor, a
known negative regulator of SNAIL protein expression18,
resulted in the downregulation of SNAIL and the upre-
gulation of MYF5 levels (Fig. 4f). Thus, our data suggest
that SNAIL is a crucial regulator of MYF5 expression in
ARMS.
In murine myoblasts, the Snail-Hdac1/2 repressive
complex binds and excludes MyoD from its targets, thus
preventing MyoD occupancy on differentiation-specific
regulatory elements18. Thus, we hypothesized that in
human ARMS SNAIL may also compete with MYOD for
binding to G/C rich E-Box sequences. Indeed, SNAIL
silencing in RH30 cells resulted in increased MYOD
binding to G/C rich E-box sequences (5′-CACCTG-3′)
(Fig. 5a), indicating that SNAIL may affect the expression
of MYOD-dependent targets.
Bioinformatical analysis revealed that the MYF5 pro-
moter contains several E-box sequences (CANNTG)
1000 bp before the transcription initiation site and four of
them were G/C rich E-boxes. Using the chromatin
immunoprecipitation assay, we demonstrated for the first
time that SNAIL binds to the MYF5 promoter in a same
way that it binds to E-cadherin promoter (Fig. 5b). Those
results were additionally verified using luciferase con-
structs under the control of MYF5 promoter (1000 bp).
The plasmid with UBC promoter was used as a positive
control and plasmid with luciferase without eukaryotic
promoter (pNL) and mCherry plasmid were used as
negative controls. Both RH30 and RH41 cells were
transfected with plasmids and siRNA against SNAIL
(siSNAIL), MYOD (siMYOD) and scrambled siRNA
(siSCR). In RH30 WT cells SNAIL silencing by siRNA
resulted in activation of MYF5 promoter, whereas MYOD
silencing did not exert any effect (Fig. 5c). Those results
indicated that SNAIL is a crucial repressor of MYF5
protein expression. SNAIL silencing by shRNA activated
MYF5 protein expression (Fig. 4b). When RH30 shSNAIL
(Fig. 5d), RH41 WT (Fig. 5e), and RH41 shSNAIL (Fig. 5f)
cells were transfected with plasmids encoding luciferase
under the control of MYF5 promoter, further SNAIL
silencing with siRNA resulted in activation of MYF5
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promoter, whereas MYOD silencing repressed it. More-
over, silencing of both MYOD and SNAIL reversed the
effects (Fig. 5d–f). Those results suggested that there is a
competition between SNAIL and MYOD for binding to
G/C rich E-boxes in MYF5 promoter.
SNAIL regulates expression of HDAC1/2 and forms
complexes with them in ARMS
HDAC1 and HDAC2 are the components of the
repressive SNAIL complex known from the literature14.
HDAC1 was strongly and HDAC2 was slightly down-
regulated in differentiated RH30 shSNAIL cells both at
mRNA (Fig. 6a) and at protein level (Fig. 6b). To confirm
that the observed effects are SNAIL dependent, we
transduced RH30 shSNAIL with lentiviral vectors
encoding GFP-P2A-SNAIL, resulting in the partial
restoration of SNAIL protein expression and reversal of
the effect on HDAC1 and HDAC2 expression (Fig. 6c). To
evaluate if SNAIL forms repressive complexes with
HDAC1/2 we performed co-immunoprecipatation assay.
Nuclear extract of protein was immunoprecipitated with
anti-SNAIL antibody. We demonstrated that SNAIL
formed indeed the complexes with HDAC1, HDAC2 and
histone H3 (Fig. 6d). Those results suggest that SNAIL-
dependent repression of E-box sequences is dependent on
interaction of SNAIL protein with HDAC1/2.
SNAIL silencing in ARMS induces expression of myogenic
factors and muscle-specific microRNAs
SNAIL silencing by shRNA in RH30 cells also increased
the expression of other myogenic factors, including
MYOD dependent or independent ones, such as MEF2A
(myocyte enhancer factor 2A), myogenin, myostatin,
MyHC (myosin heavy chain) at mRNA level (Fig. 7a).
Moreover, our study revealed an increased expression of
myogenin (Fig. 7a) and MyHC (Fig. 7b) at protein levels in
RH30 shSNAIL cells . SNAIL downregulation resulted in
appearance of the elongated cells with high MyHC level
with more than one nuclei resembling myotubes and
induced fusion of the cells (Fig. 7b). Muscle-specific
microRNAs, such as miR-1, miR-133b, miR-378a-3p, and
miR-206 were also upregulated in RH30 shSNAIL cells
(Fig. 7c). To verify if miR-206 is a mediator of SNAIL
action on MyHC level, RH30 WT cells were transfected
with miR-206 precursor (pre-miR-206) and
RH30 shSNAIL cells were transfected with miR-206
inhibitor (anti-miR-206). Transfection of RH30 WT cells
with the miR-206 precursor increased MyHC levels,
whereas inhibition of miR-206 with anti-miR sequences in
RH30 shSNAIL cells partially reversed the effect of SNAIL
on MyHC (Fig. 7d). Those results indicated that miR-206
is a mediator of SNAIL action on MyHC level.
By transfection with CRISPR/Cas9 nucleases targeting
SNAIL we developed two ARMS cell lines—RH41 and
RH30 with SNAIL knockout (Supplementary Figure 2b
and 2c). By homologous directed repair of the site-specific
Cas9-induced double strand brake within SNAIL gene
puromycin resistance gene and red fluorescent protein
(RFP) were incorporated into that locus. Cells were
selected in puromycin and subsequently sorted for the
brightest ones, what resulted in around 95% of the cells
positive for RFP (Supplementary Figure 2d and e).
Nevertheless, after 4 weeks of culture only 75% of the
RH41 cells were positive for RFP and after 6 weeks of
culture the population diminished to 60% (Supplementary
Figure 2f). Similarly, after 4 weeks of culture the popu-
lation of RFP positive RH30 cells diminished from 95 to
4% and almost disappeared after 6 weeks (Supplementary
Figure 2g). Those results from RH30 and RH41 cells
suggested that SNAIL knockout on both alleles may be a
lethal mutation and those cells are not able to survive
in vitro. Previously, we observed lethality of RH30 cells
with diminished SNAIL level after shRNA in vivo.
When we characterized those cell lines we observed that
differentiating RH41 SNAIL deficient cells acquired
spindle-shaped morphology (Supplementary Figure 2h).
RH30 CRISPR cells became elongated even in standard
culture conditions (Supplementary Figure 2j). An
(see figure on previous page)
Fig. 2 SNAIL silencing in ARMS cells induces a spindle-shaped phenotype and inhibits proliferation. a SNAIL silencing by siRNA induces the
acquisition of spindle-shaped phenotype of RH41 and RH30 cells and diminishes their proliferation. RH30 ARMS cells were transfected with siRNA
against SNAIL (siSNAIL) and a scrambled siRNA sequence (siRNA). 24 h after transfection medium was changed for a differentiating medium
containing 2% HS for the next 2 days. SNAIL silencing with siRNA for 3 days was validated by qPCR; n= 4. The morphology of the cells was visualized
with Wright’s staining (error bar represent 100 μm). Proliferation was evaluated by MTS assay; n= 3. b To stably silence the SNAIL level, RH30 cells
were transduced with shRNA lentiviral vectors targeting SNAIL (shSNAIL) and control vectors (shCTRL), and these cells were selected with puromycin.
SNAIL silencing was validated by qPCR (n= 3) and Western blotting (total cell extracts). c Stable SNAIL silencing in RH30 cells leads to the acquisition
of a spindle- shaped phenotype and reorganization of the cytoskeleton. The morphology of RH30 cells differentiated for 4 days was visualized with
Wright’s staining and for 6 days with phase contrast microscopy. d SNAIL silencing and the differentiation of RH30 cells led to cell cycle arrest at the
G0-G1 phase and diminished percentage of the cells in S phase. RH30 cells were differentiated for 7 days in medium containing 2% HS. Subsequently,
the cell cycle and BrdU incorporation in S phase were analyzed by flow cytometry—the cells were stained with anti-BrdU antibody conjugated with
APC and with 7AAD. The data in the graphs represent the mean ± SEM or are representative images of at least 3 independent experiments. *p < 0.05,
**p < 0.01, ***p < 0.001
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increased expression of myogenic factors, such as MEF2A,
myogenin, myostatin and MyHC was also observed
(Supplementary Figure 2i and 2b).
These data suggest that we discovered a novel non-
canonical mechanism of SNAIL action, which may be of
significance in the regulation of human physiological and
pathological myogenesis. Interestingly, when human pri-
mary myoblasts were cultured for several passages, what
led to their differentiation, the SNAIL level decreased
(Fig. 8a). Accordingly, the transient downregulation of
SNAIL levels by transfection with siRNA resulted in the
increased myoblasts differentiation and upregulation of
early and late differentiation factors, such as MYF5,
MRF4, myogenin and MyHC at mRNA or protein level
(Fig. 8b, c), suggesting that SNAIL plays a crucial role in
the regulation of myogenic differentiation. Indeed, SNAIL
silencing increased fusion of the cells and appearance of
multinucleated myotubes (Fig. 8d).
These results indicate for the first time that muscle-
specific miRNAs and myogenic regulatory factors are
important mediators of SNAIL anti-myogenic action in
ARMS (Fig. 8e).
Discussion
This study was undertaken to investigate the novel role
of the SNAIL transcription factor in the regulation of
ARMS growth and myogenic differentiation. SNAIL is
known as a master regulator of the growth and metastasis
of epithelial tumors, and its canonical action involves the
induction of the EMT11. Interestingly, the role of SNAIL
in the biology of mesenchymal tumors is poorly under-
stood. Here, we showed that SNAIL regulates differ-
entiation of ARMS cells. This is exerted through
regulation of myogenic factors and microRNAs. We
revealed the novel mechanism of the anti-myogenic
action of human SNAIL, a function that may be rele-
vant not only in RMS but also in other physiological
processes.
In our studies, we demonstrated for the first time that
SNAIL is a crucial negative regulator of myogenic dif-
ferentiation in ARMS through disruption of early myo-
genic transcription factors functions; therefore, SNAIL
may be a novel target for future therapies. We demon-
strated also that SNAIL is crucial for the differentiation of
human primary myoblasts. Our results are supported by
the recent papers demonstrating that, Snail regulates the
differentiation of murine myoblasts. Inhibition of Snail
leads to the induction of myogenic differentiation of these
cells18, whereas its upregulation inhibits C2C12 myotube
differentiation22. Additionally, a recent study demon-
strated that murine Snail also controls cardiomyocyte
development in embryogenesis and that its expression is
important in mesodermal commitment and
differentiation23.
RMS cells display expression of several myogenic fac-
tors, but they do not complete normal myogenic differ-
entiation1. We suggest that SNAIL may be a crucial factor
responsible for the dysregulation of myogenic differ-
entiation, leading to ARMS development. Because ERMS
may be derived from impaired differentiation of MSCs, in
our previous studies we demonstrated that the con-
stitutive activation of MET receptor signaling in MSCs
may lead to their myogenic differentiation probably by
regulation of SNAIL expression4,24. In the current study,
we describe the novel mechanism of SNAIL action in
ARMS and demonstrate that SNAIL regulates two
important early myogenic factors in RMS.
SNAIL decreases MYOD binding to G/C-rich E-boxes,
with possible implications for the physiological myogen-
esis. Early efforts to investigate the phenomenon of the
impaired differentiation of RMS focused on MYOD.
Previous papers have suggested that RMS cells express
MYOD, but it appears to be nonfunctional as a tran-
scriptional coactivator25. Based on our data, SNAIL
appears to be a novel factor that regulates MYOD tran-
scriptional activity, a finding that has been lacking
(see figure on previous page)
Fig. 3 SNAIL silencing completely blocks the growth of RH30 ARMS xenotransplants in NOD-SCID mice. a In total, 5 × 106 RH30 cells were
subcutaneously implanted into immunodeficient NOD-SCID mice, and tumor growth was investigated for 3–4 weeks and measured with a caliper.
RH30 shSNAIL cells do not form any tumors in NOD-SCID mice, whereas WT and shCTRL cells form tumors of approximately 1 g in weight and 600
cm3 in size within 21 days; n= 9–10. b Partial restoration of the SNAIL level by transduction with lentiviral vectors encoding SNAIL partially restores
the phenotype of RH30 cells. The morphology of the cells was visualized by phase contrast microscopy, and SNAIL level was evaluated by Western
blot. c Partial restoration of the SNAIL level leads to the appearance of tumors that are significantly smaller; n= 5. d RH30 tumors with partial
restoration of the SNAIL level displayed similar morphology to tumors formed by WT cells (error bar represents 20 μm) e Tumor therapy with SNAIL
siRNA slightly tends to diminish tumor growth. 5 × 106 RH30 cells were subcutaneously implanted into immunodeficient NOD-SCID mice. Next, three
injections of PBS, scrambled siRNA (siSCR) or SNAIL siRNA (siSNAIL) at dose 3 μg/kg to growing tumors were performed 9, 11, and 14 days after
implantation of the cells. Tumor volume was evaluated with caliper until day 17 and it was calculated as percentage of volume from the start of the
therapy. Weight of tumor was analyzed 17 days after the implantation. Each experimental group comprised of 3 mice. f Tumor therapy with SNAIL
siRNA resulted in appearance of differentiated tumor morphology (visualized with hematoxylin-eosin staining). g SNAIL expression level in tumors
treated with SNAIL siRNA was diminished in the regions displaying differentiating morphology (visualized with immunohistochemical staining of
FFPE sections; error bar represents 20 μm). The data in the graphs represent the mean ± SEM or are representative images. *p < 0.05, **p < 0.01,
***p < 0.001
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previously. In murine myoblasts, inhibition of the Snail
complex with Hdac1/2 leads to the induction of myogenic
differentiation by competition with MyoD for binding to
E-box sequences18. Our studies suggest that a similar
mechanism of action is also crucial for the myogenic
differentiation of human RMS cells. SNAIL mediates the
repression of different gene promoters by recruitment of
the HDAC1/HDAC2 complex14. We showed that in dif-
ferentiating ARMS cells, SNAIL recruits and regulates the
expression of HDAC1 and HDAC2.
Importantly, in RMS, the SNAIL transcription factor is
an important regulator of the MYOD-miR-206-MyHC
axis, thereby regulating myogenic differentiation. MYOD
induces the expression of numerous myogenic genes, such
as desmin, MEF2A and myogenin, that are regulated by
Snail and Slug in murine myoblasts18. One of the down-
stream mediators of MYOD is miR-206 (ref. 8), which
induces the late myogenic differentiation of RMS cells and
the expression of myosin heavy chain (MyHC). miR-206
inhibits RMS growth by the induction of differentiation26,
and miR-206 induces the expression of MyHC-positive
differentiating myoblasts27.
Both MYF5 and MYOD were demonstrated to be
important transcriptional targets regulating human RMS
growth28. In early development both factors are required
for the formation of skeletal myoblasts, and mutant mice
without both factors do not develop skeletal muscles29.
Muscle progenitors with MYOD expression but lacking
MYF5 expression may either remain highly proliferative
and developmentally arrested or differentiate into
mesenchymal progeny30, suggesting that MYOD is a
crucial regulator of the proliferation to differentiation
switch. Determination of the myogenic fate of stem cells
requires the progressive expression of MYF5, MYOD, and
subsequently myogenin (MYOG) and myofibrillar pro-
teins, such as the myosin heavy chain. Progenitors
expressing MYF5 and MYOD can divide several times
before terminal differentiation31. Accordingly, RH30
ARMS cells with silenced SNAIL are MYF5 and MYOD
positive. These cells divide in vitro but do not form any
tumors in vivo.
Importantly, our data demonstrated that SNAIL nega-
tively regulates MYF5 expression in ARMS. These data
are consistent with those of previous studies indicating
that MYF5 expression is increased in ERMS cells com-
pared with more proliferative ARMS cells. Those studies
also suggested that MYF5 is a novel RMS class pre-
dictor32. Additionally, ERMS cells positive for MYF5 do
not display pro-invasive capabilities, but they play sup-
portive roles in tumor progression33. Accordingly, PAX3/
7-FOXO1 translocation-positive ARMS cells do not dis-
play MYF5 expression32. In this study through SNAIL
silencing we demonstrated for the first time that SNAIL is
the main inhibitor of MYF5 expression in ARMS dis-
playing PAX3-FOXO1 translocation. PAX3-FOXO1
translocation is present in RH30 and RH41 cells, and it
cannot be excluded that PAX3-FOXO1 may act upstream
of SNAIL in the regulation of MYF5 expression. In mice,
Myf5 gene contains a large regulatory region 145 kb 5′
upstream of the transcription start site. Numerous reg-
ulatory transcription factors can bind to this region,
including Pax3, which binds to the −58/−56 kb distal
Myf5 enhancer34. Accordingly, in RMS, PAX3-FOXO1
also binds to a similar region35. Importantly, PAX3 is an
upstream regulator of SNAIL and SLUG in embryonic
development36. Therefore, in the future, the effect of
PAX3-FOXO1 on SNAIL activity should also be investi-
gated, as SNAIL level may be elevated in ARMS compared
to ERMS due to PAX3-FOXO1 expression in ARMS.
Interestingly, approximately 10% of satellite cells in
quiescent muscles never express MYF5. These cells dis-
play self-renewal potential37, suggesting that the induc-
tion of MYF5 expression induces subsequent
differentiation steps. The regulation of the MYF5 level
appears to be crucial in ARMS growth, and MYF5 may be
one of the most important mediators of SNAIL action.
We demonstrated a novel mechanism for SNAIL: it binds
directly to the MYF5 promoter and inhibits its expression
(see figure on previous page)
Fig. 4 SNAIL silencing induces MYF5 expression in ARMS cells. a SNAIL silencing does not significantly affect MYOD expression at the mRNA
(qPCR, n= 3) or protein level (Western blot) in undifferentiated RH30 cells and RH30 cells differentiated for 7 days in medium with 2% HS. b MYF5 is
expressed in the nuclei of RH30 shSNAIL cells. The MYF5 protein level was visualized by Western blot and by immunofluorescent staining (red color),
and the nuclei were visualized with DAPI (blue). The results are presented as merged images. The white scale bar represents 10 μm. c SNAIL silencing
induces the expression of MYF5 mRNA in both undifferentiated RH30 cells and RH30 cells differentiated for 7 days in medium with 2% HS (qPCR, n=
3) d SNAIL silencing slightly induces the expression of MYF5 mRNA in both undifferentiated RH41 cells and RH41 cells differentiated for 7 days in
medium with 2% HS (qPCR, n= 3). e Transient SNAIL silencing with siRNA in RH30 and RH41 ARMS cell lines slightly induces MYF5 expression. The
cells were transfected with siRNA against SNAIL (siSNAIL) and a scrambled siRNA sequence (siRNA). Twenty-four hours after transfection, the cells
were treated with differentiating medium containing 2% HS for the following 48 h. MYF5 levels were validated by qPCR; n= 3. f Transfection with
pre-miR-30a-5p in RH30 cells induces MYF5 expression by downregulation of SNAIL protein. RH30 cells were transfected with the miRNA precursor
pre-miR-30a-5p and pre-miR negative control (miR-neg-ctrl). Twenty-four hours after transfection, the cells were treated with differentiating medium
containing 2% HS for the following 48 h. miR-30a-5p expression relative to U6 snRNA and MYF5, MYOD expression relative to GAPDH were validated
by qPCR; n= 4. SNAIL protein level was validated by Western blot. The data represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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in ARMS tumors, thereby regulating myogenic differ-
entiation. Surprisingly, in chick embryos SNAIL was
demonstrated to be a necessary and sufficient step for the
NOTCH-dependent activation of MYF5 in the medial
border of the dermomyotome38, what suggests either its
opposite role in different species or in normal myogenesis.
In conclusion, the induction of ARMS differentiation by
SNAIL silencing leads to the complete inhibition of tumor
growth, suggesting that SNAIL may be a novel target for
differentiation-based therapies in human ARMS. The
mechanism of SNAIL action on MYF5 expression and
MYOD activity may also be of significance for further
studies on myogenesis during embryonic development.
Materials and methods
Cell culture
RMS cell lines (RH30, RH41, RD) were kindly provided
by Dr. PJ Houghton (Center for Childhood Cancer,
Columbus, OH, USA) or ordered from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
RH18 ERMS cell line was ordered from DSMZ (Leibniz
Institute DSMZ-German Collection of Microorganisms
and Cell Cultures in Germany). The cells were cultured in
DMEM high-glucose medium (Lonza Group Ltd., Basel,
Switzerland) supplemented with 10% fetal bovine serum
(FBS, EURx, Gdansk, Poland) and 50 μg/ml gentamicin
(Lonza) at 37 °C, 5% CO2 and 95% humidity. The RMS
cell lines were differentiated in DMEM low-glucose
medium (Lonza) supplemented with 2% horse serum
(HS) (Gibco, BRL Grand Island, NY, USA). At least 7 days
of incubation in differentiating medium was required to
observe single fusing cells. Shorter incubation periods
resulted only in strong elongation of the cells (acquisition
of spindle shape). The cellular morphology was visualized
using Wright’s stain (Sigma-Aldrich, St. Louis, MO, USA).
The cell lines were routinely tested for Mycoplasma
contamination using by MycoAlert™ Mycoplasma Detec-
tion Kit (Lonza). Cell line authentication was performed
by STR profiling using AmpFlSTR SGM PLUS Kit
(Applied Biosystems, Foster City, CA, USA) and sequen-
cing apparatus ABI Prism 310 Genetic Analyser (Applied
Biosystems) according to the manufacturer’s protocol.
Primary human myoblasts were isolated by our lab and
characterized as previously described39. These cells were
cultured in DMEM/F12 medium (Lonza) supplemented
with dexamethasone, insulin (both from Sigma-Aldrich)
18% FBS (EURx), EGF (R&D Systems, Minneapolis,
MN, USA), FGF (R&D), HGF (R&D) and gentamicin
(Lonza). They were differentiated in DMEM low-glucose
medium (Lonza) supplemented with 2% horse serum (HS)
(Gibco).
Production of viral vectors and transduction of cells
RH30 and RH41 cells were transduced with shRNA
Lentiviral Particles targeting SNAIL and control lentiviral
particles at an MOI of 2.5 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA; sc-38398-V and sc-108080) in 6 μg/ml
polybrene (Sigma, St. Louis, MO, USA) according to the
manufacturer’s protocol. SNAIL shRNA lentiviral particles
are a pool of concentrated, transduction-ready viral parti-
cles containing 3 different target–specific constructs that
encode 19–25 nt (plus hairpin) shRNA designed to knock
down SNAIL. Transduced cells were selected with 0.5 μg/
ml puromycin (InvivoGen, San Diego, CA, USA). Lentiviral
particles encoding GFP-P2A-SNAIL (GFP-P2A-SNAIL
@pLenti6/UbC) were produced using the Vira Power
Lentiviral Expression System (Invitrogen, Carlsbad, CA,
USA), as previously described40. RH30 shSNAIL cells were
transduced with GFP-P2A-SNAIL lentiviral vectors (at
MOI= 10) in the presence of 6 μg/ml polybrene (Sigma-
Aldrich). After 72 h the cells were subject to selection with
5 μg/ml blasticidin (InvivoGen) for 2 weeks.
Transfection with siRNA
RH30, RH41 cells and human myoblasts were trans-
fected with 20 nM siRNA against SNAIL (combination of
two Silencer Select siRNA ID variants: s13185 and s13187,
Ambion Inc., Austin, TX, USA) or scrambled control
(see figure on previous page)
Fig. 5 SNAIL is a direct transcriptional repressor of MYF5 expression and regulator of MYOD activity. a SNAIL silencing in RH30 cells induces
MYOD binding to GC rich E-Box sequences. Nuclear protein extracts from both undifferentiated RH30 cells and RH30 cells differentiated for 7 days
in medium supplemented with 2% HS were used in TransAM MyoD DNA-binding ELISA. To monitor the specificity of the assay, the wild-type
consensus oligonucleotide (wt) and mutated (mut) sequences were used as competitors for MYOD binding from cell extracts; n= 3. b SNAIL binds
to the MYF5 and E-cadherin promoters in RH30 cells. The promoter of MYF5 (~1000 bb) was screened for putative SNAIL transcription factor binding
sites and the results were validated by Chip Assay. The images depict one representative result of the ChIP assay. Proteins bound to DNA were
immunoprecipitated with the anti-SNAIL antibody, negative IgG control, positive histone H3 control and input DNA control was analyzed. Fragments
of the MYF5 and E-cadherin promoters were amplified by PCR and visualized on agarose gels stained with ethidium bromide. c SNAIL silencing by
siRNA in RH30 WT cells induces MYF5 promoter activation and luciferase expression when cells are transfected with MYF5@pNL plasmid (luciferase
under control with MYF5 promoter), whereas MYOD silencing by siRNA does not exert any effect. SNAIL and MYOD compete for binding to MYF5
promoter in RH30 shSNAIL cells (d), RH41 WT (e), and RH41 shSNAIL cells (f), when cells are transfected with MYF5@pNL plasmid and siRNA against
SNAIL, MYOD or siSCR (scrambled siRNA). The data were normalized to mCherry fluorescence level in each well. pNL (luciferase plasmid without
promoter) served as a negative control and Ubc@pNL plasmid (luciferase under control of ubiquitin C promoter) was a positive control. The data
represent the mean ± SEM or are representative images of at least 3 independent experiments. *p < 0.05
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siRNA (Silencer Select Negative Control #1 siRNA, cat.
4390844, Ambion) using Lipofectamine 2000 (Invitrogen)
or Lipofectamine RNAiMAX transfection reagent
according to vendor’s instructions. Twenty-four hours
later, the transduction medium was changed to differ-
entiating medium supplemented with 2% HS. RNA or
protein was isolated 72 h after transfection. The cellular
morphology was visualized using Wright’s stain (Sigma-
Aldrich). Proliferation of RH30 and RH41 cells
transfected on 96-well plates with siRNA was estimated
using CellTiter 96® AQueous One Solution assay (Pro-
mega, WI, USA), according to vendor’s protocol.
Transfection of cells with miRNA precursors and inhibitors
RH30 cells were transfected with 30 nM pre-miR-30a-
5p (ID: PM11062, Ambion) or 30 nM pre-miR-206 (ID:
PM10409, Ambion) miRNA precursors and pre-miR
negative controls (ID: AM17110, Ambion) or
Fig. 6 SNAIL regulates expression of HDAC1/2 and form complexes with them in ARMS. a HDAC1 and HDAC2 mRNA (qPCR, expression relative
to GAPDH, n= 3) and protein (b) (Western blot) expression is inhibited in RH30 cells differentiated for 7 days in medium with 2% HS. c Transduction
of RH30 shSNAIL with lentiviral vectors encoding SNAIL reverses the effect of SNAIL silencing on SNAIL, HDAC1, and HDAC2 protein levels, what was
additionally confirmed by densitometric analysis (n= 2). d SNAIL form complexes with HDAC1, HDAC2 and histone H3. Co-IP of SNAIL and HDAC1,
HDAC2, MYOD, histone H3 was performed. No antibody added in IP served as a negative control (neg-ctrl), whereas the input protein extract served
as a positive control. The data represent the mean ± SEM or are representative images of at least 3 independent experiments. *p < 0.05
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alternatively with 30 nM anti-miR miRNA inhibitors
against miR-206 (ID: AM10409, Ambion) and negative
controls (ID: AM17010, Ambion) using the siPORT
NeoFX transfection reagent (Ambion) according to the
manufacturer’s instructions, as described previously41.
Twenty-four hours later, the transduction medium was
changed to differentiating medium supplemented with 2%
HS. RNA was isolated 72 h after transfection.
Generation of SNAIL CRISPR knockout
8 × 104 RH30 and RH41 cells were seeded per one well
of 24-well plate. The next day the cells were transfected
with 500 ng of SNAIL CRISPR/Cas9 KO plasmid (Santa
Cruz Biotechnology, sc-400244) and 500 ng of SNAIL
HDR plasmid (Santa Cruz Biotechnology, sc-400244-
HDR) using Lipofectamine 2000 (Invitrogen) according to
vendor’s instructions. SNAIL CRISPR/Cas9 KO plasmid
consists of a pool of 3 plasmids, each encoding the Cas9
nuclease and a target-specific 20 nt guide RNA designed
for maximum knockout efficiency. SNAIL HDR plasmid
consists of a pool of 2–3 plasmids, each containing a
homology directed DNA repair (HDR) templates corre-
sponding to the cut sites generated by the SNAIL
CRISPR/Cas9 KO plasmid. Each HDR template contains
two 800 bp homology arms designed to specifically bind
to the genomic DNA surrounding the corresponding
Cas9-induced double strand DNA break site. During the
repair, the SNAIL HDR plasmid incorporates a pur-
omycin resistance gene and red fluorescence gene (RFP).
Seventy-two hours after transfection, the RH30 and
RH41 cells were selected with 0.5 μg/ml puromycin
(InvivoGen, San Diego, CA, USA) for 2 weeks and sub-
sequently they were sorted to select the cells with the
brightest expression of RFP using BD FACSAria (BD
Biosciences). Successful co-transfection of the CRISPR/
Cas9 KO Plasmid and HDR Plasmid was visually con-
firmed by detection of RFP via fluorescent microscopy
and using Attune flow cytometer (ThermoFisher
Scientific). Around 95% of the cells were positive for RFP
after the sorting.
Bioinformatical analysis of microarray data from RMS
patients
For gene expression analysis in a group of 158 RMS
patients we used data from GEO database, stored under
accession number GSE92689 (ref. 20). Background sub-
traction and data normalization was performed with affy
package[21] in R/Bioconductor and the average expres-
sion was used for further statistical analysis. Pearson
correlation of gene expression was analyzed using
GraphPad Prism software. Statistical analysis of SNAIL
expression in RMS stages and RMS subtypes was per-
formed by Mann–Whitney test using GraphPad Prism
software.
DNA and RNA isolation and reverse transcription
Total RNA was extracted using the Universal RNA
purification kit (EURx), according to the manufacturer’s
protocol. For the analysis of both miRNA and mRNA
expression, total RNA was isolated using the mirVana
miRNA Isolation Kit (Ambion). Reverse transcription of
mRNA was performed using MMLV reverse transcriptase
(Promega, Madison, WI, USA) according to the manu-
facturer’s protocol. Reverse transcription of both miRNA
and mRNA was performed using the NCode VILO
miRNA cDNA Synthesis Kit (Invitrogen), according to the
manufacturer’s protocol.
Quantitative real-time PCR
Gene expression was determined by qRT-PCR analysis
using ABI PRISM 7300 Sequence Detection System or
Quant Studio 7 Flex System (both from Applied Biosys-
tems, Foster City, CA, USA), Blank qPCR Master Mix
(EURx) and the indicated Taq-Man probes (Applied
Biosystems): human: GAPDH (Hs99999905_m1), MYF5
(Hs00271574_m1), MYOD (Hs00159528_m1), MRF4
(see figure on previous page)
Fig. 7 SNAIL silencing in ARMS regulates the expression of myogenic factors and microRNAs. a MEF2A, myogenin, myostatin and myosin
heavy chain (MyHC) expression was determined by qPCR using the ΔCT quantification method and GAPDH as housekeeping gene control in
undifferentiated RH30 cells or RH30 differentiated for 7 days in medium with 2% HS. SNAIL silencing and differentiation induce the expression of
MEF2A, myogenin, myostatin, MyHC; n= 3. Myogenin (MYOG) protein was additionally verified by Western blot analysis of nuclear extracts. b SNAIL
silencing increases the number of the spindle-shaped cells with high MyHC expression and induces their fusion. The images represent representative
merged images of immunofluorescent staining for MyHC (MyHC: red; nuclei: Hoechst, blue) of RH30 cells differentiated for 8 days in medium with 2%
HS. The scale bar represents 20 μm. Fusion index was calculated by expressing the number of nuclei within MyHC-positive cells with ≥2 nuclei as a
percentage of the total nuclei; n= 4. c SNAIL silencing in RH30 cells upregulates expression of myomiRs, such as miR-1, miR-133b, miR-378a-3p and
miR-206. The results were normalized to U6 snRNA expression level, n= 3. d Transfection of RH30 WT cells with pre-miR-206 induces the MyHC level,
whereas transfection of RH30 shSNAIL cells with anti-miR-206 partially restores the effect of SNAIL silencing on the MyHC level. RH30 cells were
transfected with the miRNA precursor pre-miR-206 and pre-miR negative control (pre-miR-ctrl), whereas RH30 shSNAIL cells were transfected with
miRNA inhibitors: anti-miR-206 or the anti-miR negative control (anti-miR-ctrl). Twenty-four hours after transfection, the cells were treated with
differentiating medium containing 2% HS for the following 48 h. miRNA expression relative to U6 snRNA and MyHC expression relative to GAPDH
were validated by qPCR (qPCR, n= 3–4). The data in the graphs represent the mean ± SEM or are representative images of at least 3 independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001
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(Hs01547104_g1), MEF2A (Hs01050409_m1), MYOS-
TATIN (Hs00976237_m1), MYOGENIN
(Hs01032275_m1), MYH2 (Hs00430042_m1), SNAI1
(Hs00195591_m1), HDAC1 (Hs02621185_s1) and
HDAC2 (Hs00231032_m1). The mRNA expression level
for all of the samples was normalized to the housekeeping
gene GAPDH (Hs99999905_m1), using the 2−ΔCt method.
For the evaluation of miRNA expression by quantitative
real-time PCR, SYBR Green qPCR Master Mix (EURx)
and universal reverse primer from the NCode VILO
miRNA cDNA Synthesis Kit (Invitrogen) were used with
the indicated forward primers. The miRNAs expression
levels were quantified using the 2−ΔCt method, using







Protein (either nuclear and cytoplasmic fractions or
total extracts) was isolated using the Nuclear Extract Kit
(Active Motif, La Hulpe Belgium) according to the man-
ufacturer’s protocol. The protein concentration was
measured using the Bio-Rad Protein Assay (Bio-Rad,
Hercules, California, USA) according to the manu-
facturer’s protocol. Western blot was performed using the
anti-GAPDH rabbit mAb (14C10; Cell Signaling Tech-
nology, Leiden, The Netherlands), the anti-α-tubulin mAb
(DM1A; Calbiochem, EMD Chemicals Inc San Diego,
USA), the anti-histone H3 (ab1791; Abcam, Cambridge
UK), the anti-SNAIL mouse mAb (L70G2; Cell Signaling),
the anti-MYOD rabbit pAb (M-318; Santa Cruz, CA,
USA), the anti-HDAC1 rabbit pAb (Poly6074 clone;
Biolegend, San Diego CA, USA), the anti-HDAC2 mouse
mAb (Biolegend, 3F3/HDAC2), anti-myogenin mouse
mAb (F5D, sc-12732, Santa Cruz Biotechnology), anti-fast
myosin skeletal heavy chain mouse mAb antibody
(MyHC, MY-32, ab51263, Abcam), and secondary anti-
rabbit and anti-mouse antibodies conjugated with
horseradish peroxidase (HRP, Santa Cruz Biotechnology)
as previously described24.
Transcriptional activity studies
The activation of MYOD transcription factor and its
binding to E-Box sequences were evaluated using isolated
nuclear protein extracts from RH30 cells and TransAM®
MyoD DNA-binding ELISA enzyme-linked immunosor-
bent assay (ELISA; Active Motif) for activated MYOD
transcription factor according to the manufacturer’s
protocol and using proteins from nuclear extracts. To
monitor the specificity of the assay the WT consensus
oligonucleotide and mutated sequences were used as
competitors for MYOD binding from cell extracts.
Bioinformatic analysis
The promoter of MYF5 (~1000 bb) was screened for
putative SNAIL transcription factor binding sites using a
TF prediction tool called ConSite (http://consite.genereg.
net/)42. The results were then compared with other TF
prediction tools.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using SimpleChip Enzymatic
Chromatin IP Kit (Cell Signaling Technology) according
to the manufacturer’s protocol. For ChIP assays 10 µg of
antibodies against SNAIL (SNAI1 E-18: sc10432X, Santa
Cruz Biotechnology), 10 µg of the positive control histone
H3 (D2B12 XP Rabbit mAb Chip formulated, Cell Sig-
naling Technology) and 1 µg of the negative control IgG
from the kit were used. After immunoprecipitation, the
DNA was isolated using spin columns from the kit and
eluted in 50 µl Elution Reagent C. PCR was performed
with 2 µl of immunoprecipitated material and the pro-
ducts were analyzed on an 1.5% agarose gel, and visualized
using a gel documentation system. The following primers
were used to quantify SNAIL binding to the MYF5 pro-
moter region 500 and 1000 bp before the translation start
site and to the E-cadherin promoter (positive control for
SNAIL targets).
MYF5 primer fragment 1 forward
(see figure on previous page)
Fig. 8 SNAIL silencing in human myoblasts increases expression of myogenic factors. a SNAIL expression in human myoblasts diminishes with
subsequent passages (qPCR, n= 4). b Human myoblasts were transfected with siRNA against SNAIL (siSNAIL) and with a scrambled siRNA sequence
(siRNA) or they were treated with transfection reagent (mock). 24 h after transfection they were treated with a differentiating medium containing 2%
HS for the next 48 h. SNAIL silencing was validated by Western blot. SNAIL silencing increased the myogenin and MyHC protein levels (Western blot).
c Expression of SNAIL, MYF5, MYOD, MRF4, myogenin and MyHC was determined by qPCR with ΔCT quantification method and GAPDH as a
housekeeping gene control. SNAIL silencing and differentiation induces expression of the analyzed myogenic factors. d SNAIL silencing increases the
number of the myotubes with high MyHC expression and induces their fusion. The images are representative merged images of immunofluorescent
staining for MyHC (MyHC: red; nuclei: Hoechst, blue) of myotubes. The scale bar represents 100 μm. Fusion index was calculated by expressing the
number of nuclei within MyHC-positive myotubes with ≥2 nuclei as a percentage of the total nuclei; n= 4. e Mechanism of action of SNAIL
transcription factor on myogenic differentiation of ARMS. Data on graphs are represented as mean ± SEM. *p < 0.05, n= 4
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5′-GCCAGCTGAAAGGGATTTCTATT-3′
MYF5 primer fragment 1 reverse
5′-CACGTCCATCCTGCTGAGAG-3′
MYF5 primer fragment 2 forward
5′-AAAACTGGGCTTCTTCTGTTGG-3′
MYF5 primer fragment 2 reverse
5′-GACCAAGGCAGTCCAACTTTTT-3′
ECADH promoter primer forward
5′-TAGAGGGTCACCGCGTCTAT-3′
ECADH promoter primer reverse
5′-TCACAGGTGCTTTGCAGTTC-3′
Luciferase activity assay
NanoLuc® luciferase plasmids variants (pNL plasmids)
were ordered from Promega, WI, USA. pNL plasmids
with luciferase under control of human ubiquitin C
(UBC@pNL) and MYF5 promoter (MYF5@pNL) were
generated by us. Promoter fragments were cloned from







Primers were designed to introduce restriction sites
appropriate for following ligation with linearized pNL
plasmids using T4 DNA Ligase (Invitrogen, USA). Bac-
terial transformations of One Shot™ TOP10 Chemically
Competent E. coli (Invitrogen, USA) with generated
UBC@pNL and MYF5@pNL plasmids were performed
and LB Agar plates with 100 µg/ml ampicillin were used
for bacterial selection. 6 clones of each plasmid were
purified from selected bacterial colonies using QIAfilter
Plasmid Maxi Kit (Qiagen, Germany). Sequences of MYF5
and UbC promoters in pNL plasmids were confirmed
with Sanger sequencing—BigDye™ Terminator v3.1 Cycle
Sequencing Kit (Thermo) and Applied Biosystems 3500
Genetic Analyzer.
RH30 and RH41 cells were transfected with pNL,
UBC@pNL and MYF5@pNL plasmids using Lipofecta-
mine 2000 (Invitrogen) transfection reagent according to
the manufacturer’s instructions, utilizing 500 ng of pNL
plasmids, and 100 ng mCherry plasmid, and 20 nM siRNA
against SNAIL (combination of two Silencer Select siRNA
ID variants: s13185 and s13187, Ambion Inc., Austin, TX,
USA) or siRNA against MYOD (combination of two
Silencer Select siRNA ID variants: s9231 and s9229) or
scrambled control siRNA (Silencer Select Negative Con-
trol #1 siRNA, cat. 4390844, Ambion) and 1.0 μl of
Lipofectamine 2000 per one well of a 24-well plate. Forty-
eight hours after transfection, the cells were evaluated for
activity of the secreted NanoLuc® luciferase using Nano-
Glo® Luciferase Assay (Promega, WI, USA) according to
the vendor’s protocol. The results of luminescence were
normalized to mCherry fluorescence level in each well.
Luminescence and fluorescence signals were analyzed
using Tecan Spark 10M microplate reader (Tecan Trad-
ing AG, Switzerland).
Co-immunoprecipitation
RH30 cells were grown to confluence on 100mm plates
and nuclear extracts were prepared using the Nuclear
Complex Co-IP Kit (Active Motif) according to vendor’s
protocol. 100 μg of nuclear extract was used per IP reac-
tion and incubated with either 2 μg of anti-SNAIL anti-
body (Sc-10432, Santa Cruz, CA, USA) or no antibody
using IP Low Buffer from the kit. Protein G beads were
added to each IP reaction. Following the IP, 2× Laemmli
Sample Buffer was added to each IP reaction, samples
were boiled and run on SDS-PAGE gel. Western blot
analysis was performed using the anti-HDAC1 rabbit pAb
(Poly6074 clone; Biolegend, San Diego CA, USA), the
anti-HDAC2 mouse mAb (Biolegend, 3F3/HDAC2), the
anti-histone H3 (ab1791; Abcam, Cambridge UK), anti-
SNAIL mouse mAb (L70G2; Cell Signaling) and second-
ary anti-rabbit and anti-mouse antibodies conjugated with
horseradish peroxidase (HRP, Santa Cruz Biotechnology)
as previously described. The input RH30 nuclear extract
was run as a positive control for western blot.
Cell cycle and BrdU incorporation
For the assessment of DNA content and BrdU incor-
poration, RH30 cells were differentiated for 7 days in
DMEM medium with 2% HS and then they were analyzed
using APC BrdU flow Kit (BD Pharmingen, CA, USA)
using Attune flow cytometer (ThermoFisher Scientific),
according to vendor’s protocol.
Immunofluorescent staining
RH30 cells or myoblasts were fixed in 4% formaldehyde
(POCH) in PBS, permeabilized in 0.1% TritonX-100
(Sigma-Aldrich), blocked in 1% bovine serum albumin
(BSA, Sigma-Aldrich), incubated with rabbit anti-MYF5
monoclonal antibody (ab125078, Abcam) or anti-fast
myosin skeletal heavy chain antibody (MyHC, MY-32,
ab51263, Abcam), and then incubated with secondary
goat anti-rabbit or anti-mouse antibodies conjugated with
Alexa Fluor 555 (Life Technologies) and sometimes with
Hoechst. The stained slides were mounted in Vectashield
mounting medium with DAPI (Vector Laboratories Inc.
Burlingame, CA, USA) or Dako Fluorescence Mounting
Medium (Dako, Denmark). For visualization of mor-
phology, the cells were stained with Wright’s dye (Sigma-
Aldrich). Labeling was assessed by fluorescence micro-
scopy using an Olympus BX51 or IX70 microscope
(Olympus Corporation, Tokyo, Japan) and Olympus
XC50 camera with cellSens Dimension software (both
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from Olympus). The images were processed using cell-
Sens Dimension software or ImageJ software (National
Institute of Health, USA). To quantify RH30 cells and
myoblasts fusion, we calculated the fusion index by
expressing the number of nuclei within MyHC-positive
cells with ≥2 nuclei as a percentage of the total nuclei.
In vivo experiments
Animal experiments were approved by the Local Ethics
Committee in Krakow in Poland. In total, 5 × 106 RH30
cells were injected subcutaneously into 6- to 8-week-old
NOD-SCID mice. Each experimental group contained 4
to 5 animals, and all of the experiments were repeated
twice. Tumor size was evaluated using a caliper. Tumor
volume was estimated using the formula V=D × d2 × 0.5
(where V is the tumor volume, D is the largest dimension,
and d is the smallest dimension). After 3 to 4 weeks, the
mice were euthanized, and their tumors were harvested.
After the evaluation of tumor weight, the tumor sections
were fixed in formalin. The tumor sections were stained
with hematoxylin-eosin to visualize tumor morphology
using Dako EnVision Detection Systems (Dako Polska Sp.
z o.o.), as previously described24.
To evaluate if treatment of growing tumors with SNAIL
siRNA can affect tumor growth, 5 × 106 RH30 cells were
injected subcutaneously into 6- to 8-week-old NOD-SCID
mice. After tumors reached an average size of 60 mm3,
mice were injected intratumorally with PBS, scrambled
siRNA (siSCR, Silencer Select Negative Control #1 siRNA,
Ambion) or siRNA against SNAIL (combination of two
Silencer Select siRNA ID variants: s13185 and s13187,
Ambion) at dose 3 μg/kg of body weight. Tumor growth
was monitored with caliper . Three injections were per-
formed 9, 11, and 14 days after implantation of the cells.
Tumor volume was evaluated with caliper until day 17
and it was calculated as percentage of volume from the
start of the therapy. Weight of tumor was analyzed
17 days after the implantation. The tumor sections were
stained with hematoxylin-eosin to visualize tumor mor-
phology using Dako EnVision Detection Systems (Dako
Polska Sp. z o.o.) and after deparaffinization they were
stained immunohistochemically, as described pre-
viously24, with anti-SNAIL primary mouse monoclonal
antibody to evaluate SNAIL expression (1:50; Santa Cruz
Biotechnology; G-7: sc-271977). Each experimental group
contained 3 mice.
Statistical analysis
Unless stated otherwise, the results show the mean ±
standard error of the mean (SEM) of at least 3 to 4
independent experiments. Statistical analysis was per-
formed by one-way analysis of variance (ANOVA) with
Tukey post-test or Student’s t-test using GraphPad Prism
software. Differences with a p-value less than 0.05 were
considered statistically significant. n value in figure
legends describes the number of independent biological
experiments.
Acknowledgements
We would like to acknowledge Malgorzata Sekula for transduction of RH30
cells with lentiviral vectors encoding shRNA; Grazyna Drabik for the
histopathological analysis of tumors; Elzbieta Trzesniowska-Popiel for her
technical assistance in immunohistochemical staining; Artur Nieszporek and
Grazyna Adamek for technical help with RNA or protein isolation; Kazimierz
Weglarczyk for technical help with BD FACSAria; Marta Kot for technical help
with Attune Flow Cytometer. KS was a recipient of the Foundation for Polish
Science’s START scholarship for outstanding young scientists and the Polish
Ministry of Science and Higher Education’s scholarship for outstanding young
scientists. The project was supported by the research grants from the National
Science Centre in Poland to MM: 2013/09/B/NZ5/00769 and to KS: 2015/17/D/
NZ5/02202.
Author contributions
K.S. designed, planned and conducted most of the experiments in vitro and
in vivo, analyzed data, performed the statistical analysis and wrote the
manuscript. A.K. was involved in characterization of the stable cell line
RH30 shSNAIL (morphology, expression profile, tumor growth). E.T. performed
Chip Assay and STR profiling. B.S. was involved in experiments with human
myoblasts (qPCR analysis). T.A. and P.K. generated plasmids and viral vectors. P.
K. performed bioinformatical analysis of microarray data stored in GEO
database. A.U. was involved in Western blot analysis and development of
CRISPR SNAIL knockout cells. B.B. measured tumor growth in vivo. M.K. was
involved in designing experiments and revising the manuscript. M.M.
conceived the study, designed and coordinated the study, wrote manuscript.
All the authors revised the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41419-018-0693-8).
Received: 5 December 2017 Revised: 30 April 2018 Accepted: 10 May 2018
References
1. Hettmer, S. & Wagers, A. J. Muscling in: uncovering the origins of rhabdo-
myosarcoma. Nat. Med. 16, 171–173 (2010).
2. El Demellawy, D., McGowan-Jordan, J., de Nanassy, J., Chernetsova, E. & Nasr,
A. Update on molecular findings in rhabdomyosarcoma. Pathology 49,
238–246 (2017).
3. Yu, P. Y. & Guttridge, D. C. Dysregulated myogenesis in rhabdomyosarcoma.
Curr. Top. Dev. Biol. 126, 285–297 (2018).
4. Szewczyk, B., Skrzypek, K. & Majka, M. Targeting MET receptor in rhab-
domyosarcoma: rationale and progress. Curr. Drug Targets 18, 98–107
(2017).
5. Charytonowicz, E., Cordon-Cardo, C., Matushansky, I. & Ziman, M. Alveolar
rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer
Lett. 279, 126–136 (2009).
6. Asakura, A. & Rudnicki, M. A. Rhabdomyosarcomagenesis-Novel pathway
found. Cancer Cell 4, 421–422 (2003).
7. Bentzinger, C. F., Wang, Y. X. & Rudnicki, M. A. Building muscle: molecular
regulation of myogenesis. Cold Spring Harb. Perspect. Biol. 4, a008342 (2012).
8. Rosenberg, M. I., Georges, S. A., Asawachaicharn, A., Analau, E. & Tapscott, S. J.
MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206.
J. Cell Biol. 175, 77–85 (2006).
Skrzypek et al. Cell Death and Disease  (2018) 9:643 Page 19 of 20
Official journal of the Cell Death Differentiation Association
9. Püsküllüoglu, M., Lukasiewicz, E., Miekus, K., Jarocha, D. & Majka, M. Differential
expression of Snail1 transcription factor and Snail1-related genes in alveolar
and embryonal rhabdomyosarcoma subtypes. Folia Histochem. Cytobiol. 48,
671–677 (2010).
10. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev.
Mol. Cell Biol. 3, 155–166 (2002).
11. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour
progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7,
415–428 (2007).
12. Wang, Y., Shi, J., Chai, K., Ying, X. & Zhou, B. P. The role of snail in EMT and
tumorigenesis. Curr. Cancer Drug Targets 13, 963–972 (2013).
13. Barrallo-Gimeno, A. & Nieto, M. A. The snail genes as inducers of cell move-
ment and survival: implications in development and cancer. Development 132,
3151–3161 (2005).
14. Peinado, H., Ballestar, E., Esteller, M. & Cano, A. Snail mediates E-cadherin
repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/
HDAC2 complex. Mol. Cell. Biol. 24, 306–319 (2004).
15. Stanisavljevic, J. et al. Snail1-expressing fibroblasts in the tumor micro-
environment display mechanical properties that support metastasis. Cancer
Res. 75, 284–295 (2014).
16. Rowe, R. G. et al. Mesenchymal cells reactivate Snail1 expression to drive three-
dimensional invasion programs. J. Cell Biol. 184, 399–408 (2009).
17. Francí, C. et al. Expression of Snail protein in tumor-stroma interface. Oncogene
25, 5134–5144 (2006).
18. Soleimani, V. D. et al. Snail regulates MyoD binding-site occupancy to direct
enhancer switching and differentiation-specific transcription in myogenesis.
Mol. Cell 47, 457–468 (2012).
19. Ignatius, M. S. et al. The NOTCH1/SNAIL1/MEF2C pathway regulates growth
and self-renewal in embryonal rhabdomyosarcoma. Cell Rep. 19, 2304–2318
(2017).
20. Davicioni, E. et al. Identification of a PAX-FKHR gene expression signature that
defines molecular classes and determines the prognosis of alveolar rhabdo-
myosarcomas. Cancer Res. 66, 6936–6946 (2006).
21. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. Affy-analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20, 307–315 (2004).
22. Batlle, R. et al. Snail1 controls TGF-β responsiveness and differentiation of
mesenchymal stem cells. Oncogene 32, 3381–3389 (2013).
23. Lin, Y. et al. Snail1-dependent control of embryonic stem cell pluripotency and
lineage commitment. Nat. Commun. 5, 3070 (2014).
24. Skrzypek, K. et al. Constitutive activation of MET signaling impairs myogenic
differentiation of rhabdomyosarcoma and promotes its development and
progression. Oncotarget 6, 31378–31398 (2015).
25. Tapscott, S. J., Thayer, M. J. & Weintraub, H. Deficiency in rhabdomyosarcomas
of a factor required for MyoD activity and myogenesis. Science 259,
1450–1453 (1993).
26. Taulli, R. et al. Validation of met as a therapeutic target in alveolar and
embryonal rhabdomyosarcoma. Cancer Res. 66, 4742–4749 (2006).
27. Kim, H. K., Lee, Y. S., Sivaprasad, U., Malhotra, A. & Dutta, A. Muscle-specific
microRNA miR-206 promotes muscle differentiation. J. Cell. Biol. 174, 677–687
(2006).
28. Tenente, I. M. et al. Myogenic regulatory transcription factors regulate growth
in rhabdomyosarcoma. eLife 6, e19214 (2017).
29. Rudnicki, M. A. et al. MyoD or Myf-5 is required for the formation of skeletal
muscle. Cell 75, 1351–1359 (1993).
30. Kablar, B., Krastel, K., Tajbakhsh, S. & Rudnicki, M. A. Myf5 and MyoD activation
define independent myogenic compartments during embryonic develop-
ment. Dev. Biol. 258, 307–318 (2003).
31. Wang, Y. X., Dumont, N. A. & Rudnicki, M. A. Muscle stem cells at a glance. J.
Cell. Sci. 127, 4543–4548 (2014).
32. Zibat, A. et al. Activation of the hedgehog pathway confers a poor prognosis
in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Onco-
gene 29, 6323–6330 (2010).
33. Ignatius, M. S. et al. In vivo imaging of tumor-propagating cells, regional tumor
heterogeneity, and dynamic cell movements in embryonal rhabdomyo-
sarcoma. Cancer Cell 21, 680–693 (2012).
34. Buchberger, A., Freitag, D. & Arnold, H.-H. A homeo-paired domain-binding
motif directs Myf5 expression in progenitor cells of limb muscle. Development
134, 1171–1180 (2007).
35. Cao, L. et al. Genome-wide identification of PAX3-FKHR binding sites in
rhabdomyosarcoma reveals candidate target genes important for develop-
ment and cancer. Cancer Res. 70, 6497–6508 (2010).
36. Plouhinec, J.-L. et al. Pax3 and Zic1 trigger the early neural crest gene reg-
ulatory network by the direct activation of multiple key neural crest specifiers.
Dev. Biol. 386, 461–472 (2014).
37. Kuang, S., Kuroda, K., Le Grand, F. & Rudnicki, M. A. Asymmetric self-renewal
and commitment of satellite stem cells in muscle. Cell 129, 999–1010 (2007).
38. Sieiro, D., Rios, A. C., Hirst, C. E. & Marcelle, C. Cytoplasmic NOTCH and
membrane-derived β-catenin link cell fate choice to epithelial-mesenchymal
transition during myogenesis. eLife 5, e14847 (2016).
39. Jarocha, D., Stangel-Wojcikiewicz, K., Basta, A. & Majka, M. Efficient myoblast
expansion for regenerative medicine use. Int. J. Mol. Med. 34, 83–91 (2014).
40. Adamus, T., Konieczny, P., Sekuła, M., Sułkowski, M. & Majka, M. The strategy of
fusion genes construction determines efficient expression of introduced
transcription factors. Acta Biochim. Pol. 61, 773–778 (2014).
41. Skrzypek, K. et al. Interplay between heme oxygenase-1 and miR-378 affects
non-small cell lung carcinoma growth, vascularization, and metastasis. Anti-
oxid. Redox Signal. 19, 644–660 (2013).
42. Sandelin, A., Wasserman, W. W. & Lenhard, B. ConSite: web-based prediction of
regulatory elements using cross-species comparison. Nucleic Acids Res. 32,
W249–W252 (2004).
Skrzypek et al. Cell Death and Disease  (2018) 9:643 Page 20 of 20
Official journal of the Cell Death Differentiation Association
